Updates in cardiac amyloidosis: a review.

PubWeight™: 2.21‹?› | Rank: Top 2%

🔗 View Article (PMC 3487372)

Published in J Am Heart Assoc on April 24, 2012

Authors

Sanjay M Banypersad1, James C Moon, Carol Whelan, Philip N Hawkins, Ashutosh D Wechalekar

Author Affiliations

1: National Amyloidosis Centre, UCL Medical School, UK (S.M.B., C.W., P.N.H., A.D.W.) ; The Heart Hospital, UK (S.M.B., J.C.M.) ; University College London, UK (S.M.B., C.W.).

Associated clinical trials:

The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis. (ATTRact-AS) | NCT03029026

Articles citing this

T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J (2014) 1.77

Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol (2014) 0.86

Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study. Heart Vessels (2013) 0.84

Infiltrative Cardiomyopathies. Clin Med Insights Cardiol (2015) 0.83

Amyloid Light-Chain Amyloidosis Manifesting as Heart Failure with Preserved Ejection Fraction in a Patient with Hyper-Immunoglobulin E-emia. Am J Case Rep (2016) 0.82

Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis. Int J Cardiovasc Imaging (2015) 0.79

Regression of cardiac amyloidosis after stem cell transplantation assessed by cardiovascular magnetic resonance imaging. Circulation (2014) 0.79

A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir. Front Cardiovasc Med (2015) 0.79

Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr (2015) 0.77

Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol (2014) 0.77

Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2013) 0.77

Recent advances in the noninvasive strategies of cardiac amyloidosis. Heart Fail Rev (2016) 0.77

Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies. Arrhythm Electrophysiol Rev (2013) 0.76

Cardiac amyloidosis in a heart transplant patient - A case report and retrospective analysis of amyloidosis evolution. Intractable Rare Dis Res (2015) 0.75

Amyloidosis involving the respiratory system: 5-year's experience of a multi-disciplinary group's activity. Ann Thorac Med (2015) 0.75

A systemic disease un…suspected by physical examination. BMJ Case Rep (2014) 0.75

Congestive heart failure: a case of protein misfolding. Hawaii J Med Public Health (2014) 0.75

Value of tissue Doppler-derived Tei index and two-dimensional speckle tracking imaging derived longitudinal strain on predicting outcome of patients with light-chain cardiac amyloidosis. Int J Cardiovasc Imaging (2017) 0.75

Cardiac amyloidosis: a report of two cases. Indian Heart J (2014) 0.75

Chronic diarrhea as the initial clinical manifestation of light-chain amyloidosis with cardiac involvement despite negative duodenal and rectal biopsies. Exp Clin Cardiol (2013) 0.75

Heavy and Light chain amyloidosois presenting as complete heart block: A rare presentation of a rare disease. Indian J Nephrol (2015) 0.75

Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging. Can J Cardiol (2016) 0.75

Primary systemic amyloidosis as a real diagnostic challenge - case study. Cent Eur J Immunol (2014) 0.75

Unusual case of ATTR amyloidosis with cardiac manifestation and situs inversus totalis. Clin Res Cardiol (2017) 0.75

An unusual case of systemic amyloid causing constrictive heart failure. Neth Heart J (2016) 0.75

Differentiation of light-chain cardiac amyloidosis from hypertrophic cardiomyopathy using myocardial mechanical parameters by velocity vector imaging echocardiography. Int J Cardiovasc Imaging (2016) 0.75

Next-generation endomyocardial biopsy: the potential of confocal and super-resolution microscopy. Heart Fail Rev (2015) 0.75

Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma. Am J Case Rep (2017) 0.75

Diffuse Myocardial Fibrosis Reduces Electrocardiographic Voltage Measures of Left Ventricular Hypertrophy Independent of Left Ventricular Mass. J Am Heart Assoc (2017) 0.75

Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction. Arq Bras Cardiol (2017) 0.75

Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy. Eur Radiol (2017) 0.75

Sudden cardiac death from structural heart diseases in adults: imaging findings with cardiovascular computed tomography and magnetic resonance. Int J Cardiovasc Imaging (2016) 0.75

Articles cited by this

(truncated to the top 100)

Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75

Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation (2005) 5.85

Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation (2010) 5.68

Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol (1995) 5.51

Diagnosis and management of the cardiac amyloidoses. Circulation (2005) 3.96

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med (1997) 3.65

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43

Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38

Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17

Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood (2009) 3.00

Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A (1990) 2.87

Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol (2008) 2.82

The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM (1998) 2.81

A primer of amyloid nomenclature. Amyloid (2007) 2.70

Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging (2009) 2.41

Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med (2005) 2.33

Tabulation of human transthyretin (TTR) variants, 2003. Amyloid (2003) 2.23

Left ventricular torsion by two-dimensional speckle tracking echocardiography in patients with diastolic dysfunction and normal ejection fraction. J Am Soc Echocardiogr (2008) 2.03

Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood (2004) 2.01

Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med (2000) 1.94

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 1.93

Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging (2010) 1.93

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation (2003) 1.93

Amyloid heart disease. Prog Cardiovasc Dis (2010) 1.91

Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid (2010) 1.91

Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J (2004) 1.84

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81

Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke (2011) 1.70

Dangerous small B-cell clones. Blood (2006) 1.70

Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol (2005) 1.65

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet (2003) 1.64

Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol (2005) 1.55

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood (2006) 1.54

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood (2007) 1.48

Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid (2006) 1.34

Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med (2008) 1.30

Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart (2011) 1.28

Digoxin sensitivity in amyloid cardiomyopathy. Circulation (1981) 1.28

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood (2010) 1.27

Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol (2008) 1.26

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm (2007) 1.24

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22

Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res (2006) 1.20

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol (2007) 1.20

Perspectives in treatment of AL amyloidosis. Br J Haematol (2007) 1.17

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve (2006) 1.17

Systemic amyloidosis presenting with angina pectoris. Ann Intern Med (1999) 1.16

Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr (2009) 1.10

Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation (2007) 1.10

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol (2010) 1.08

Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol (2009) 1.08

Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy. Am J Cardiol (2007) 1.05

Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol (2008) 1.05

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation (2010) 1.04

The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med (1977) 1.03

Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) (2010) 1.03

Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci U S A (2010) 1.02

Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol (1998) 1.02

Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant (2008) 1.00

Amyloid in endomyocardial biopsies. Virchows Arch (2010) 1.00

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood (2004) 0.99

Focal monomorphic ventricular tachycardia as the first manifestation of amyloid cardiomyopathy. Indian Pacing Electrophysiol J (2010) 0.98

MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol (2007) 0.96

'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis. Heart (2008) 0.95

Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant (2007) 0.95

Solid organ transplantation in AL amyloidosis. Am J Transplant (2010) 0.94

Autonomic neuropathies. Curr Opin Neurol (2002) 0.93

Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation (2009) 0.93

Rotational mechanics of the left ventricle in AL amyloidosis. Echocardiography (2010) 0.92

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood (2010) 0.91

Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol (1997) 0.91

Clinical, electrocardiographic and echocardiographic findings in significant cardiac amyloidosis detected only at necropsy: comparison with cases diagnosed in life. Arq Bras Cardiol (2008) 0.90

CT and MR imaging findings in patients with acquired heart disease at risk for sudden cardiac death. Radiographics (2009) 0.89

Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest (1993) 0.88

Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid (2009) 0.88

Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol (1997) 0.88

Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J Magn Reson Imaging (2009) 0.88

Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw (2007) 0.88

Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med (2005) 0.87

Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis (2008) 0.86

Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg (2007) 0.86

Echocardiographic evaluation of cardiac amyloid. Curr Cardiol Rep (2010) 0.86

The prevalence of isolated atrial amyloid. J Pathol (1987) 0.85

MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. AJR Am J Roentgenol (2010) 0.85

Myocardial contrast echocardiography in biopsy-proven primary cardiac amyloidosis. Eur J Echocardiogr (2008) 0.84

Isolated atrial amyloid contains atrial natriuretic peptide: a report of six cases. Br Heart J (1986) 0.84

Selective binding of nifedipine to amyloid fibrils. Am J Cardiol (1985) 0.84

The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid (2000) 0.84

Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid (2009) 0.83

Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol (2005) 0.83

The neglected entity of familial cardiac amyloidosis in African Americans. Ethn Dis (2002) 0.83

Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl (2010) 0.81

Annual electrocardiograms consistent with silent progression of cardiac involvement in sporadic familial amyloid polyneuropathy: a case report. Intern Med (2010) 0.81

Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy. Am J Cardiol (1997) 0.79

Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology (2007) 0.79

Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica (2011) 0.79

Experimental AA amyloidogenesis is associated with differential expression of extracellular matrix genes. Amyloid (1999) 0.79

Articles by these authors

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17

Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation (2010) 5.68

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64

Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19

Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging (2011) 4.78

Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47

T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21

Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07

Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86

Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53

Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol (2010) 3.50

Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35

Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J (2004) 3.15

Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging (2013) 3.14

Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12

Switching statins. BMJ (2006) 2.94

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74

Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58

Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 2.49

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34

Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20

Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19

Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation (2006) 2.18

Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01

Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging (2013) 1.99

Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91

Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart (2013) 1.86

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80

Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson (2012) 1.67

Systemic light chain amyloidosis: an update for treating physicians. Blood (2013) 1.63

Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.61

Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiovasc Magn Reson (2013) 1.60

Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56

Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart (2011) 1.55

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood (2006) 1.54

Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51

Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation (2005) 1.43

Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci (2013) 1.43

Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging (2012) 1.40

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica (2008) 1.38

Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36

Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2009) 1.34

Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart (2012) 1.33

Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32

Novel imaging techniques for diffuse myocardial fibrosis. Future Cardiol (2011) 1.29

Human plasma fibrinogen is synthesized in the liver. Blood (2006) 1.27

Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience. J Cardiovasc Med (Hagerstown) (2007) 1.26

Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26

Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging (2012) 1.25

Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat (2014) 1.23

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22

Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol (2011) 1.21

Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20

AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood (2008) 1.20

Quantification of left ventricular trabeculae using fractal analysis. J Cardiovasc Magn Reson (2013) 1.18

Perspectives in treatment of AL amyloidosis. Br J Haematol (2007) 1.17

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol (2006) 1.13

Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid (2005) 1.13

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol (2006) 1.12

Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol (2004) 1.11

The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum (2011) 1.09

Systemic amyloidosis in England: an epidemiological study. Br J Haematol (2013) 1.08

Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol (2008) 1.07

Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol (2006) 1.06

Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04

Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol (2002) 1.04

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol (2010) 1.04

Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. J Biol Chem (2013) 1.04

The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J (2012) 1.03

Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med (2005) 1.02

Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A (2013) 1.01

Cardiovascular magnetic resonance in cardiac sarcoidosis with MR conditional pacemaker in situ. J Cardiovasc Magn Reson (2011) 1.01

Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol (2014) 1.01

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther (2011) 1.00

Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev (2015) 1.00